1
|
Yan J, Siwakoti P, Shaw S, Bose S, Kokil G, Kumeria T. Porous silicon and silica carriers for delivery of peptide therapeutics. Drug Deliv Transl Res 2024:10.1007/s13346-024-01609-7. [PMID: 38819767 DOI: 10.1007/s13346-024-01609-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/15/2024] [Indexed: 06/01/2024]
Abstract
Peptides have gained tremendous popularity as biological therapeutic agents in recent years due to their favourable specificity, diversity of targets, well-established screening methods, ease of production, and lower cost. However, their poor physiological and storage stability, pharmacokinetics, and fast clearance have limited their clinical translation. Novel nanocarrier-based strategies have shown promise in overcoming these issues. In this direction, porous silicon (pSi) and mesoporous silica nanoparticles (MSNs) have been widely explored as potential carriers for the delivery of peptide therapeutics. These materials possess several advantages, including large surface areas, tunable pore sizes, and adjustable pore architectures, which make them attractive carriers for peptide delivery systems. In this review, we cover pSi and MSNs as drug carriers focusing on their use in peptide delivery. The review provides a brief overview of their fabrication, surface modification, and interesting properties that make them ideal peptide drug carriers. The review provides a systematic account of various studies that have utilised these unique porous carriers for peptide delivery describing significant in vitro and in vivo results. We have also provided a critical comparison of the two carriers in terms of their physicochemical properties and short-term and long-term biocompatibility. Lastly, we have concluded the review with our opinion of this field and identified key areas for future research for clinical translation of pSi and MSN-based peptide therapeutic formulations.
Collapse
Affiliation(s)
- Jiachen Yan
- School of Materials Science and Engineering, The University of New South Wales, Sydney, NSW, 2052, Australia
| | - Prakriti Siwakoti
- School of Materials Science and Engineering, The University of New South Wales, Sydney, NSW, 2052, Australia
- Australian Centre for Nanomedicine, The University of New South Wales, Sydney, NSW, 2052, Australia
| | - Siuli Shaw
- Centre for Medical Biotechnology, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, 201301, India
| | - Sudeep Bose
- Centre for Medical Biotechnology, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, 201301, India
- Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Noida, Uttar Pradesh, 201301, India
| | - Ganesh Kokil
- School of Materials Science and Engineering, The University of New South Wales, Sydney, NSW, 2052, Australia.
- Australian Centre for Nanomedicine, The University of New South Wales, Sydney, NSW, 2052, Australia.
| | - Tushar Kumeria
- School of Materials Science and Engineering, The University of New South Wales, Sydney, NSW, 2052, Australia.
- Australian Centre for Nanomedicine, The University of New South Wales, Sydney, NSW, 2052, Australia.
- School of Pharmacy, The University of Queensland, Woolloongabba, QLD, 4102, Australia.
| |
Collapse
|
2
|
Sahandi Zangabad P, Abousalman Rezvani Z, Tong Z, Esser L, Vasani RB, Voelcker NH. Recent Advances in Formulations for Long-Acting Delivery of Therapeutic Peptides. ACS APPLIED BIO MATERIALS 2023; 6:3532-3554. [PMID: 37294445 DOI: 10.1021/acsabm.3c00193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Recent preclinical and clinical studies have focused on the active area of therapeutic peptides due to their high potency, selectivity, and specificity in treating a broad range of diseases. However, therapeutic peptides suffer from multiple disadvantages, such as limited oral bioavailability, short half-life, rapid clearance from the body, and susceptibility to physiological conditions (e.g., acidic pH and enzymolysis). Therefore, high peptide dosages and dose frequencies are required for effective patient treatment. Recent innovations in pharmaceutical formulations have substantially improved therapeutic peptide administration by providing the following advantages: long-acting delivery, precise dose administration, retention of biological activity, and improvement of patient compliance. This review discusses therapeutic peptides and challenges in their delivery and explores recent peptide delivery formulations, including micro/nanoparticles (based on lipids, polymers, porous silicon, silica, and stimuli-responsive materials), (stimuli-responsive) hydrogels, particle/hydrogel composites, and (natural or synthetic) scaffolds. This review further covers the applications of these formulations for prolonged delivery and sustained release of therapeutic peptides and their impact on peptide bioactivity, loading efficiency, and (in vitro/in vivo) release parameters.
Collapse
Affiliation(s)
- Parham Sahandi Zangabad
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutics Science, Monash University, Parkville Campus, Parkville, Victoria 3052, Australia
- Melbourne Centre for Nanofabrication, Victorian Node of the Australian National Fabrication Facility, Clayton, Victoria 3168, Australia
| | - Zahra Abousalman Rezvani
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutics Science, Monash University, Parkville Campus, Parkville, Victoria 3052, Australia
- Commonwealth Scientific and Industrial Research Organization (CSIRO), Clayton, Victoria 3168, Australia
| | - Ziqiu Tong
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutics Science, Monash University, Parkville Campus, Parkville, Victoria 3052, Australia
| | - Lars Esser
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutics Science, Monash University, Parkville Campus, Parkville, Victoria 3052, Australia
- Commonwealth Scientific and Industrial Research Organization (CSIRO), Clayton, Victoria 3168, Australia
| | - Roshan B Vasani
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutics Science, Monash University, Parkville Campus, Parkville, Victoria 3052, Australia
| | - Nicolas H Voelcker
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutics Science, Monash University, Parkville Campus, Parkville, Victoria 3052, Australia
- Melbourne Centre for Nanofabrication, Victorian Node of the Australian National Fabrication Facility, Clayton, Victoria 3168, Australia
- Department of Materials Science and Engineering, Monash University, Clayton, Victoria 3800, Australia
| |
Collapse
|
3
|
Rama B, Ribeiro AJ. Role of nanotechnology in the prolonged release of drugs by the subcutaneous route. Expert Opin Drug Deliv 2023; 20:559-577. [PMID: 37305971 DOI: 10.1080/17425247.2023.2214362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2022] [Accepted: 05/11/2023] [Indexed: 06/13/2023]
Abstract
INTRODUCTION Subcutaneous physiology is distinct from other parenteral routes that benefit the administration of prolonged-release formulations. A prolonged-release effect is particularly convenient for treating chronic diseases because it is associated with complex and often prolonged posologies. Therefore, drug-delivery systems focused on nanotechnology are proposed as alternatives that can overcome the limitations of current therapeutic regimens and improve therapeutic efficacy. AREAS COVERED This review presents an updated systematization of nanosystems, focusing on their applications in highly prevalent chronic diseases. Subcutaneous-delivered nanosystem-based therapies comprehensively summarize nanosystems, drugs, and diseases and their advantages, limitations, and strategies to increase their translation into clinical applications. An outline of the potential contribution of quality-by-design (QbD) and artificial intelligence (AI) to the pharmaceutical development of nanosystems is presented. EXPERT OPINION Although recent academic research and development (R&D) advances in the subcutaneous delivery of nanosystems have exhibited promising results, pharmaceutical industries and regulatory agencies need to catch up. The lack of standardized methodologies for analyzing in vitro data from nanosystems for subcutaneous administration and subsequent in vivo correlation limits their access to clinical trials. There is an urgent need for regulatory agencies to develop methods that faithfully mimic subcutaneous administration and specific guidelines for evaluating nanosystems.
Collapse
Affiliation(s)
- B Rama
- Faculdade de Farmácia, Universidade de Coimbra, Coimbra, Portugal
| | - A J Ribeiro
- Faculdade de Farmácia, Universidade de Coimbra, Coimbra, Portugal
- Genetics of Cognitive Disfunction, i3S, IBMC, Porto, Portugal
| |
Collapse
|
4
|
Zhang DX, Tieu T, Esser L, Wojnilowicz M, Lee CH, Cifuentes-Rius A, Thissen H, Voelcker NH. Differential Surface Engineering Generates Core-Shell Porous Silicon Nanoparticles for Controlled and Targeted Delivery of an Anticancer Drug. ACS APPLIED MATERIALS & INTERFACES 2022; 14:54539-54549. [PMID: 36469497 DOI: 10.1021/acsami.2c16370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
An approach to differentially modify the internal surface of porous silicon nanoparticles (pSiNPs) with hydrophobic dodecene and the external surface with antifouling poly-N-(2-hydroxypropyl) acrylamide (polyHPAm) as well as a cell-targeting peptide was developed. Specifically, to generate these core-shell pSiNPs, the interior surface of a porous silicon (pSi) film was hydrosilylated with 1-dodecene, followed by ultrasonication to create pSiNPs. The new external surfaces were modified by silanization with a polymerization initiator, and surface-initiated atom transfer radical polymerization was performed to introduce polyHPAm brushes. Afterward, a fraction of the polymer side chain hydroxyl groups was activated to conjugate cRGDfK─a peptide with a high affinity and selectivity for the ανβ3 integrin receptor that is overexpressed in prostate and melanoma cancers. Finally, camptothecin, a hydrophobic anti-cancer drug, was successfully loaded into the pores. This drug delivery system showed excellent colloidal stability in a cell culture medium, and the in vitro drug release kinetics could be fine-tuned by the combination of internal and external surface modifications. In vitro studies by confocal microscopy and flow cytometry revealed improved cellular association attributed to cRGDfK. Furthermore, the cell viability results showed that the drug-loaded and peptide-functionalized nanoparticles had enhanced cytotoxicity toward a C4-2B prostate carcinoma cell line in both 2D cell culture and a 3D spheroid model.
Collapse
Affiliation(s)
- De-Xiang Zhang
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
- Commonwealth Scientific and Industrial Research Organisation (CSIRO) Manufacturing, Clayton, Victoria 3168, Australia
| | - Terence Tieu
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
- Commonwealth Scientific and Industrial Research Organisation (CSIRO) Manufacturing, Clayton, Victoria 3168, Australia
| | - Lars Esser
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
- Commonwealth Scientific and Industrial Research Organisation (CSIRO) Manufacturing, Clayton, Victoria 3168, Australia
| | - Marcin Wojnilowicz
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
- Commonwealth Scientific and Industrial Research Organisation (CSIRO) Manufacturing, Clayton, Victoria 3168, Australia
| | - Chieh-Hua Lee
- Department of Biological Science and Technology, China Medical University, Taichung 40402, Taiwan
| | - Anna Cifuentes-Rius
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Helmut Thissen
- Commonwealth Scientific and Industrial Research Organisation (CSIRO) Manufacturing, Clayton, Victoria 3168, Australia
| | - Nicolas H Voelcker
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
- Commonwealth Scientific and Industrial Research Organisation (CSIRO) Manufacturing, Clayton, Victoria 3168, Australia
- Melbourne Centre for Nanofabrication, Victorian Node of Australian National Fabrication Facility, Clayton, Victoria 3168, Australia
| |
Collapse
|
5
|
Kumeria T, Wang J, Kim B, Park JH, Zuidema JM, Klempner M, Cavacini L, Wang Y, Sailor MJ. Enteric Polymer-Coated Porous Silicon Nanoparticles for Site-Specific Oral Delivery of IgA Antibody. ACS Biomater Sci Eng 2022; 8:4140-4152. [PMID: 36210772 PMCID: PMC10036216 DOI: 10.1021/acsbiomaterials.0c01313] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Porous silicon (pSi) nanoparticles are loaded with Immunoglobulin A-2 (IgA2) antibodies, and the assembly is coated with pH-responsive polymers on the basis of the Eudragit family of enteric polymers (L100, S100, and L30-D55). The temporal release of the protein from the nanocomposite formulations is quantified following an in vitro protocol simulating oral delivery: incubation in simulated gastric fluid (SGF; at pH 1.2) for 2 h, followed by a fasting state simulated intestinal fluid (FasSIF; at pH 6.8) or phosphate buffer solution (PBS; at pH 7.4). The nanocomposite formulations display a negligible release in SGF, while more than 50% of the loaded IgA2 is released in solutions at a pH of 6.8 (FasSIF) or 7.4 (PBS). Between 21 and 44% of the released IgA2 retains its functional activity. A capsule-based system is also evaluated, where the IgA2-loaded particles are packed into a gelatin capsule and the capsule is coated with either EudragitL100 or EudragitS100 polymer for a targeted release in the small intestine or the colon, respectively. The capsule-based formulations outperform polymer-coated nanoparticles in vitro, preserving 45-54% of the activity of the released protein.
Collapse
Affiliation(s)
- Tushar Kumeria
- Department of Chemistry and Biochemistry, University of California, San Diego, California 92093, United States
- School of Materials Science and Engineering, University of New South Wales-Sydney, Sydney, NSW 2052, Australia
| | - Joanna Wang
- Materials Science and Engineering Program, University of California, San Diego, California 92093, United States
| | - Byungji Kim
- Materials Science and Engineering Program, University of California, San Diego, California 92093, United States
| | - Ji-Ho Park
- Department of Bio and Brain Engineering, KAIST, Daejeon 34141, Korea
| | - Jonathan M Zuidema
- Department of Chemistry and Biochemistry, University of California, San Diego, California 92093, United States
| | - Mark Klempner
- MassBiologics of the University of Massachusetts Medical School, Boston, Massachusetts 02126, United States
| | - Lisa Cavacini
- MassBiologics of the University of Massachusetts Medical School, Boston, Massachusetts 02126, United States
| | - Yang Wang
- MassBiologics of the University of Massachusetts Medical School, Boston, Massachusetts 02126, United States
| | - Michael J Sailor
- Department of Chemistry and Biochemistry, University of California, San Diego, California 92093, United States
| |
Collapse
|
6
|
Wang Z, Rich J, Hao N, Gu Y, Chen C, Yang S, Zhang P, Huang TJ. Acoustofluidics for simultaneous nanoparticle-based drug loading and exosome encapsulation. MICROSYSTEMS & NANOENGINEERING 2022; 8:45. [PMID: 35498337 PMCID: PMC9051122 DOI: 10.1038/s41378-022-00374-2] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/31/2021] [Revised: 02/15/2022] [Accepted: 03/07/2022] [Indexed: 05/08/2023]
Abstract
Nanocarrier and exosome encapsulation has been found to significantly increase the efficacy of targeted drug delivery while also minimizing unwanted side effects. However, the development of exosome-encapsulated drug nanocarriers is limited by low drug loading efficiencies and/or complex, time-consuming drug loading processes. Herein, we have developed an acoustofluidic device that simultaneously performs both drug loading and exosome encapsulation. By synergistically leveraging the acoustic radiation force, acoustic microstreaming, and shear stresses in a rotating droplet, the concentration, and fusion of exosomes, drugs, and porous silica nanoparticles is achieved. The final product consists of drug-loaded silica nanocarriers that are encased within an exosomal membrane. The drug loading efficiency is significantly improved, with nearly 30% of the free drug (e.g., doxorubicin) molecules loaded into the nanocarriers. Furthermore, this acoustofluidic drug loading system circumvents the need for complex chemical modification, allowing drug loading and encapsulation to be completed within a matter of minutes. These exosome-encapsulated nanocarriers exhibit excellent efficiency in intracellular transport and are capable of significantly inhibiting tumor cell proliferation. By utilizing physical forces to rapidly generate hybrid nanocarriers, this acoustofluidic drug loading platform wields the potential to significantly impact innovation in both drug delivery research and applications.
Collapse
Affiliation(s)
- Zeyu Wang
- Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708 USA
| | - Joseph Rich
- Department of Biomedical Engineering, Duke University, Durham, NC 27708 USA
| | - Nanjing Hao
- Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708 USA
| | - Yuyang Gu
- Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708 USA
| | - Chuyi Chen
- Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708 USA
| | - Shujie Yang
- Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708 USA
| | - Peiran Zhang
- Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708 USA
| | - Tony Jun Huang
- Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708 USA
| |
Collapse
|
7
|
Kamakura R, Raza GS, Mäkilä E, Riikonen J, Kovalainen M, Ueta Y, Lehto VP, Salonen J, Herzig KH. Colonic Delivery of α-Linolenic Acid by an Advanced Nutrient Delivery System Prolongs Glucagon-Like Peptide-1 Secretion and Inhibits Food Intake in Mice. Mol Nutr Food Res 2021; 66:e2100978. [PMID: 34882959 PMCID: PMC9285029 DOI: 10.1002/mnfr.202100978] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2021] [Revised: 11/30/2021] [Indexed: 12/20/2022]
Abstract
Scope Nutrients stimulate the secretion of glucagon‐like peptide‐1 (GLP‐1), an incretin hormone, secreted from enteroendocrine L‐cells which decreases food intake. Thus, GLP‐1 analogs are approved for the treatment of obesity, yet cost and side effects limit their use. L‐cells are mainly localized in the distal ileum and colon, which hinders the utilization of nutrients targeting GLP‐1 secretion. This study proposes a controlled delivery system for nutrients, inducing a prolonged endogenous GLP‐1 release which results in a decrease food intake. Methods and Results α‐Linolenic acid (αLA) was loaded into thermally hydrocarbonized porous silicon (THCPSi) particles. In vitro characterization and in vivo effects of αLA loaded particles on GLP‐1 secretion and food intake were studied in mice. A total of 40.4 ± 3.2% of loaded αLA is released from particles into biorelevant buffer over 24 h, and αLA loaded THCPSi significantly increased in vitro GLP‐1 secretion. Single‐dose orally given αLA loaded mesoporous particles increased plasma active GLP‐1 levels at 3 and 4 h and significantly reduced the area under the curve of 24 h food intake in mice. Conclusions αLA loaded THCPSi particles could be used to endogenously stimulate sustain gastrointestinal hormone release and reduce food intake.
Collapse
Affiliation(s)
- Remi Kamakura
- Research Unit of Biomedicine, Faculty of Medicine, University of Oulu, Oulu, FI-90220, Finland
| | - Ghulam Shere Raza
- Research Unit of Biomedicine, Faculty of Medicine, University of Oulu, Oulu, FI-90220, Finland
| | - Ermei Mäkilä
- Department of Physics and Astronomy, University of Turku, Turku, FI-20014, Finland
| | - Joakim Riikonen
- Department of Applied Physics, Faculty of Science and Forestry, University of Eastern Finland, Kuopio, FI-70211, Finland
| | - Miia Kovalainen
- Research Unit of Biomedicine, Faculty of Medicine, University of Oulu, Oulu, FI-90220, Finland
| | - Yoichi Ueta
- Department of Physiology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, 807-8555, Japan
| | - Vesa-Pekka Lehto
- Department of Applied Physics, Faculty of Science and Forestry, University of Eastern Finland, Kuopio, FI-70211, Finland
| | - Jarno Salonen
- Department of Physics and Astronomy, University of Turku, Turku, FI-20014, Finland
| | - Karl-Heinz Herzig
- Research Unit of Biomedicine, Faculty of Medicine, University of Oulu, Oulu, FI-90220, Finland.,Department of Pediatric Gastroenterology and Metabolic Diseases, Pediatric Institute, Poznan University of Medical Sciences, Poznań, 60-572, Poland
| |
Collapse
|
8
|
Tamarov K, Wang JTW, Kari J, Happonen E, Vesavaara I, Niemelä M, Perämäki P, Al-Jamal KT, Xu W, Lehto VP. Comparison between Fluorescence Imaging and Elemental Analysis to Determine Biodistribution of Inorganic Nanoparticles with Strong Light Absorption. ACS APPLIED MATERIALS & INTERFACES 2021; 13:40392-40400. [PMID: 34405988 PMCID: PMC8414481 DOI: 10.1021/acsami.1c11875] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Accepted: 07/30/2021] [Indexed: 06/13/2023]
Abstract
Black porous silicon nanoparticles (BPSi NPs) are known as highly efficient infrared light absorbers that are well-suitable for photothermal therapy (PTT) and photoacoustic imaging (PAI). PTT and PAI require a sufficient number of effectively light-absorbing NPs to be accumulated in tumor after intravenous administration. Herein, biodistribution of PEGylated BPSi NPs with different sizes (i.e., 140, 200, and 300 nm in diameter) is investigated after intravenous administration in mice. BPSi NPs were conjugated with fluorescent dyes Cy5.5 and Cy7.5 to track them in vitro and in vivo, respectively. Optical imaging with an in vivo imaging system (IVIS) was found to be an inadequate technique to assess the biodistribution of the dye-labeled BPSi NPs in vivo because the intrinsic strong absorbance of the BPSi NPs interfered fluorescence detection. This challenge was resolved via the use of inductively coupled plasma optical emission spectrometry to analyze ex vivo the silicon content in different tissues and tumors. The results indicated that most of the polyethylene glycol-coated BPSi NPs were found to accumulate in the liver and spleen after intravenous injection. The smallest 140 nm particles accumulated the most in tumors at an amount of 9.5 ± 3.4% of the injected dose (concentration of 0.18 ± 0.08 mg/mL), the amount known to produce sufficient heat for cancer PTT. Furthermore, the findings from the present study also suggest that techniques other than optical imaging should be considered to study the organ biodistribution of NPs with strong light absorbance properties.
Collapse
Affiliation(s)
- Konstantin Tamarov
- Department
of Applied Physics, Faculty of Science and Forestry, University of Eastern Finland, Kuopio 70211, Finland
| | - Julie Tzu-Wen Wang
- School
of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences &
Medicine, King’s College London, London SE1 9NH, U.K.
| | - Juuso Kari
- Department
of Applied Physics, Faculty of Science and Forestry, University of Eastern Finland, Kuopio 70211, Finland
| | - Emilia Happonen
- Department
of Applied Physics, Faculty of Science and Forestry, University of Eastern Finland, Kuopio 70211, Finland
| | - Ilkka Vesavaara
- Research
Unit of Sustainable Chemistry, University
of Oulu, Oulu 90570, Finland
| | - Matti Niemelä
- Research
Unit of Sustainable Chemistry, University
of Oulu, Oulu 90570, Finland
| | - Paavo Perämäki
- Research
Unit of Sustainable Chemistry, University
of Oulu, Oulu 90570, Finland
| | - Khuloud T. Al-Jamal
- School
of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences &
Medicine, King’s College London, London SE1 9NH, U.K.
| | - Wujun Xu
- Department
of Applied Physics, Faculty of Science and Forestry, University of Eastern Finland, Kuopio 70211, Finland
| | - Vesa-Pekka Lehto
- Department
of Applied Physics, Faculty of Science and Forestry, University of Eastern Finland, Kuopio 70211, Finland
| |
Collapse
|
9
|
Shreyash N, Sonker M, Bajpai S, Tiwary SK. Review of the Mechanism of Nanocarriers and Technological Developments in the Field of Nanoparticles for Applications in Cancer Theragnostics. ACS APPLIED BIO MATERIALS 2021; 4:2307-2334. [PMID: 35014353 DOI: 10.1021/acsabm.1c00020] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Cancer cannot be controlled by the usage of drugs alone, and thus, nanotechnology is an important technique that can provide the drug with an impetus to act more effectively. There is adequate availability of anticancer drugs that are classified as alkylating agents, hormones, or antimetabolites. Nanoparticle (NP) carriers increase the residence time of the drug, thereby enhancing the survival rate of the drug, which otherwise gets washed off owing to the small size of the drug particles by the excretory system. For example, for enhancing the circulation, a coating of nonfouling polymers like PEG and dextran is done. Famous drugs such as doxorubicin (DOX) are commonly encapsulated inside the nanocomposite. The various classes of nanoparticles are used to enhance drug delivery by aiding it to fight against the tumor. Targeted therapy aims to attack the cells with features common to the cancer cells while minimizing damage to the normal cell, and these therapies work in one in four ways. Some block the cancer cells from reproducing newer cells, others release toxic substances to kill the cancer cells, some stimulate the immune system to destroy the cancer cells, and some block the growth of more blood vessels around cancer cells, which starve the cells of the nutrients, which is needed for their growth. This review aims to testify the advancements nanotechnology has brought in cancer therapy, and its statements are supported with recent research findings and clinical trial results.
Collapse
|
10
|
Pérez KS, Warther D, Calixto ME, Méndez-Blas A, Sailor MJ. Harnessing the Aqueous Chemistry of Silicon: Self-Assembling Porous Silicon/Silica Microribbons. ACS APPLIED MATERIALS & INTERFACES 2019; 11:27162-27169. [PMID: 31310495 DOI: 10.1021/acsami.9b03611] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
The synthesis of microribbons based on the assembly of porous silicon nanoparticles (pSiNPs) in a silica matrix is reported. The formation of these structures is driven by dissolution and reprecipitation of silica derived from the NPs upon drying of an aqueous colloidal dispersion. The process generates composite films that fracture into filaments due to geometric stresses associated with drying of the film on a curved surface. By controlling NP concentration, solvent, and temperature during the evaporation process, well-defined microribbons with a rectangular cross section of ∼25 × 100 microns and lengths on the order of 1 cm are formed. Partial thermal oxidation of the ribbons generates luminescent Si-SiO2 core-shell composites, and complete oxidation generates porous SiO2 ribbons with retention of the mesoporous nanostructure. The pores can be infiltrated with daunorubicin as a model drug, and the resulting material shows sustained release of the chemotherapeutic for more than 70 days.
Collapse
Affiliation(s)
- Karina S Pérez
- Department of Chemistry and Biochemistry , University of California San Diego , La Jolla , California 92093 , United States
| | - David Warther
- Department of Chemistry and Biochemistry , University of California San Diego , La Jolla , California 92093 , United States
| | - Ma Estela Calixto
- Instituto de Física , Benemérita Universidad Autónoma de Puebla , A. P. J48, 72570 Puebla , México
| | - Antonio Méndez-Blas
- Instituto de Física , Benemérita Universidad Autónoma de Puebla , A. P. J48, 72570 Puebla , México
| | - Michael J Sailor
- Department of Chemistry and Biochemistry , University of California San Diego , La Jolla , California 92093 , United States
| |
Collapse
|
11
|
Bolhassani A. Improvements in chemical carriers of proteins and peptides. Cell Biol Int 2019; 43:437-452. [PMID: 30672055 DOI: 10.1002/cbin.11108] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2018] [Accepted: 01/19/2019] [Indexed: 01/02/2023]
Abstract
The successful intracellular delivery of biologically active proteins and peptides plays an important role for therapeutic applications. Indeed, protein/peptide delivery could overcome some problems of gene therapy, for example, controlling the expression levels and the integration of transgene into the host cell genome. Thus, protein/peptide drug delivery showed a promising and safe approach for treatment of cancer and infectious diseases. Due to the unique physical and chemical properties of proteins, their production (e.g., isolation, purification & formulation) and delivery represented significant challenges in pharmaceutical studies. Modification in the structural moieties of these protein/peptide drugs could improve their solubility, stability, crystallinity, lipophilicity, enzymatic susceptibility and targetability, and subsequently, therapies and cures against various diseases. Using the structural modification of protein/peptide, their delivery provided overall higher success rates including high specificity, high activity, bioreactivity and safety. Recently, biotechnological and pharmaceutical companies have tried to find novel techniques for the modifications and improve delivery systems/carriers. However, each carrier has its own benefits and drawbacks, and an appropriate carrier is often established by the physicochemical properties of protein or peptide, the ideal route of injection, and clinical characteristics of therapy. In this review, an attempt was made to give an overview on the chemical carriers for proteins and peptides as well as the recent advances in this field.
Collapse
Affiliation(s)
- Azam Bolhassani
- Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
| |
Collapse
|
12
|
Salonen J, Mäkilä E. Thermally Carbonized Porous Silicon and Its Recent Applications. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2018; 30:e1703819. [PMID: 29484727 DOI: 10.1002/adma.201703819] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/09/2017] [Revised: 09/08/2017] [Indexed: 06/08/2023]
Abstract
Recent progress in research on thermally carbonized porous silicon (TCPSi) and its applications is reported. Despite a slow start, thermal carbonization has now started to gain interest mainly due to new emerging areas for applications. These new areas, such as optical sensing, drug delivery, and energy storage, require stable surface chemistry and physical properties. TCPSi is known to have all of these desired properties. Herein, the above-listed properties of TCPSi are summarized, and the carbonization processes, functionalization, and characterization of TCPSi are reviewed. Moreover, some of the emerging fields of TCPSi applications are discussed and recent advances in the fields are introduced.
Collapse
Affiliation(s)
- Jarno Salonen
- Industrial Physics Laboratory, Department of Physics and Astronomy, University of Turku, FI-20014, Turku, Finland
| | - Ermei Mäkilä
- Industrial Physics Laboratory, Department of Physics and Astronomy, University of Turku, FI-20014, Turku, Finland
| |
Collapse
|
13
|
Understanding the Connection between Nanoparticle Uptake and Cancer Treatment Efficacy using Mathematical Modeling. Sci Rep 2018; 8:7538. [PMID: 29795392 PMCID: PMC5967303 DOI: 10.1038/s41598-018-25878-8] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2018] [Accepted: 04/23/2018] [Indexed: 12/12/2022] Open
Abstract
Nanoparticles have shown great promise in improving cancer treatment efficacy while reducing toxicity and treatment side effects. Predicting the treatment outcome for nanoparticle systems by measuring nanoparticle biodistribution has been challenging due to the commonly unmatched, heterogeneous distribution of nanoparticles relative to free drug distribution. We here present a proof-of-concept study that uses mathematical modeling together with experimentation to address this challenge. Individual mice with 4T1 breast cancer were treated with either nanoparticle-delivered or free doxorubicin, with results demonstrating improved cancer kill efficacy of doxorubicin loaded nanoparticles in comparison to free doxorubicin. We then developed a mathematical theory to render model predictions from measured nanoparticle biodistribution, as determined using graphite furnace atomic absorption. Model analysis finds that treatment efficacy increased exponentially with increased nanoparticle accumulation within the tumor, emphasizing the significance of developing new ways to optimize the delivery efficiency of nanoparticles to the tumor microenvironment.
Collapse
|
14
|
McInnes SJP, Santos A, Kumeria T. Porous Silicon Particles for Cancer Therapy and Bioimaging. NANOONCOLOGY 2018. [DOI: 10.1007/978-3-319-89878-0_9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
15
|
Kovalainen M, Kamakura R, Riikonen J, Finnilä M, Nissinen T, Rantanen J, Niemelä M, Perämäki P, Mäkinen M, Herzig KH, Lehto VP. Biodegradation of inorganic drug delivery systems in subcutaneous conditions. Eur J Pharm Biopharm 2017; 122:113-125. [PMID: 29056485 DOI: 10.1016/j.ejpb.2017.10.014] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2017] [Revised: 10/16/2017] [Accepted: 10/18/2017] [Indexed: 11/28/2022]
Abstract
Despite extensive efforts to develop delivery systems for oral administration, subcutaneous (s.c.) injection remains the most common way to administer peptide drugs. To limit the number of frequent injections, sustained release systems that are easy to produce, suitable for various drugs, safe and biodegradable are urgently needed. Porous silicon (PSi) has been recognized to be one of the most promising materials for s.c. peptide delivery, but its biodegradation in s.c. tissue has not been studied in vivo, despite extensive in vitro research. In the present study, differently modified PSi microparticles were injected s.c. in mice, after which the morphology of the particles was thoroughly studied with transmission electron microscopy, micro-computed tomography and X-ray diffraction. Furthermore, histopathology of the s.c. tissue was analyzed to evaluate biocompatibility. To the best of our knowledge, this is the first systematic study which reveals the degradation behavior of various PSi materials in vivo. The PSi surface chemistry significantly affected the biodegradation rate of the s.c. injected microparticles. The most hydrophobic PSi microparticles with hydrocarbonized surface showed the lowest biodegradation rate while the hydrophilic microparticles, with oxide surface, degraded the fastest. The results from different empirical methods complemented each other to deduce the biodegradation mechanism of the inorganic delivery system, providing useful information for future development of s.c. carriers.
Collapse
Affiliation(s)
- M Kovalainen
- Research Unit of Biomedicine & Biocenter of Oulu, Faculty of Medicine, P.O. Box 5000, FI-90014 University of Oulu, Finland.
| | - R Kamakura
- Research Unit of Biomedicine & Biocenter of Oulu, Faculty of Medicine, P.O. Box 5000, FI-90014 University of Oulu, Finland
| | - J Riikonen
- Department of Applied Physics, Faculty of Science and Forestry, University of Eastern Finland, P.O. Box 1627, 70210 Kuopio, Finland
| | - M Finnilä
- Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, P.O. Box 5000, FI-90014 University of Oulu, Finland
| | - T Nissinen
- Department of Applied Physics, Faculty of Science and Forestry, University of Eastern Finland, P.O. Box 1627, 70210 Kuopio, Finland
| | - J Rantanen
- Department of Applied Physics, Faculty of Science and Forestry, University of Eastern Finland, P.O. Box 1627, 70210 Kuopio, Finland
| | - M Niemelä
- Research Unit of Sustainable Chemistry, Faculty of Technology, P.O.Box 3000, FI-90014 University of Oulu, Finland
| | - P Perämäki
- Research Unit of Sustainable Chemistry, Faculty of Technology, P.O.Box 3000, FI-90014 University of Oulu, Finland
| | - M Mäkinen
- Cancer Research and Translational Medicine Research Unit, Faculty of Medicine, P.O. Box 5000, FI-90014 University of Oulu, Finland
| | - K H Herzig
- Research Unit of Biomedicine & Biocenter of Oulu, Faculty of Medicine, P.O. Box 5000, FI-90014 University of Oulu, Finland; Department of Gastroenterology and Metabolism, Poznan University of Medical Sciences, Poznan, Poland; Medical Research Center (MRC) and Oulu University Hospital, Oulu, Finland
| | - V P Lehto
- Department of Applied Physics, Faculty of Science and Forestry, University of Eastern Finland, P.O. Box 1627, 70210 Kuopio, Finland
| |
Collapse
|
16
|
Kumeria T, McInnes SJP, Maher S, Santos A. Porous silicon for drug delivery applications and theranostics: recent advances, critical review and perspectives. Expert Opin Drug Deliv 2017; 14:1407-1422. [DOI: 10.1080/17425247.2017.1317245] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Tushar Kumeria
- School of Chemical Engineering, The University of Adelaide, Adelaide, Australia
| | - Steven J. P. McInnes
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Future Industries Institute, University of South Australia, Mawson Lakes, Australia
| | - Shaheer Maher
- School of Chemical Engineering, The University of Adelaide, Adelaide, Australia
- Faculty of Pharmacy, Assiut University, Assiut, Egypt
| | - Abel Santos
- School of Chemical Engineering, The University of Adelaide, Adelaide, Australia
- Institute for Photonics and Advanced Sensing (IPAS), The University of Adelaide, Adelaide, Australia
- ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), The University of Adelaide, Adelaide, Australia
| |
Collapse
|
17
|
Jantas D, Piotrowski M, Lason W. An Involvement of PI3-K/Akt Activation and Inhibition of AIF Translocation in Neuroprotective Effects of Undecylenic Acid (UDA) Against Pro-Apoptotic Factors-Induced Cell Death in Human Neuroblastoma SH-SY5Y Cells. J Cell Biochem 2016; 116:2882-95. [PMID: 26012840 DOI: 10.1002/jcb.25236] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2015] [Accepted: 05/15/2015] [Indexed: 01/29/2023]
Abstract
Undecylenic acid (UDA), a naturally occurring 11-carbon unsaturated fatty acid, has been used for several years as an economical antifungal agent and a nutritional supplement. Recently, the potential usefulness of UDA as a neuroprotective drug has been suggested based on the ability of this agent to inhibit μ-calpain activity. In order to verify neuroprotective potential of UDA, we tested protective efficacy of this compound against cell damage evoked by pro-apoptotic factors (staurosporine and doxorubicin) and oxidative stress (hydrogen peroxide) in human neuroblastoma SH-SY5Y cells. We showed that UDA partially protected SH-SY5Y cells against the staurosporine- and doxorubicin-evoked cell death; however, this effect was not connected with its influence on caspase-3 activity. UDA decreased the St-induced changes in mitochondrial and cytosolic AIF level, whereas in Dox-model it affected only the cytosolic AIF content. Moreover, UDA (1-40 μM) decreased the hydrogen peroxide-induced cell damage which was connected with attenuation of hydrogen peroxide-mediated necrotic (PI staining, ADP/ATP ratio) and apoptotic (mitochondrial membrane potential, caspase-3 activation, AIF translocation) changes. Finally, we demonstrated that an inhibitor of PI3-K/Akt (LY294002) but not MAPK/ERK1/2 (U0126) pathway blocked the protection mediated by UDA in all tested models of SH-SY5Y cell injury. These in vitro data point to UDA as potentially effective neuroprotectant the utility of which should be further validated in animal studies.
Collapse
Affiliation(s)
- Danuta Jantas
- Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
| | - Marek Piotrowski
- Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences, Krakow, Poland
| | - Wladyslaw Lason
- Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
| |
Collapse
|
18
|
Small JC, Dam HM, Siegel JL, Crepinsek AJ, Neal TA, Althoff AA, Line NS, Porter LA. Alkyl-functionalization of porous silicon via multimode microwave-assisted hydrosilylation. Polyhedron 2016. [DOI: 10.1016/j.poly.2015.12.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
19
|
Kovalainen M, Mönkäre J, Riikonen J, Pesonen U, Vlasova M, Salonen J, Lehto VP, Järvinen K, Herzig KH. Novel delivery systems for improving the clinical use of peptides. Pharmacol Rev 2016; 67:541-61. [PMID: 26023145 DOI: 10.1124/pr.113.008367] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Peptides have long been recognized as a promising group of therapeutic substances to treat various diseases. Delivery systems for peptides have been under development since the discovery of insulin for the treatment of diabetes. The challenge of using peptides as drugs arises from their poor bioavailability resulting from the low permeability of biological membranes and their instability. Currently, subcutaneous injection is clinically the most common administration route for peptides. This route is cost-effective and suitable for self-administration, and the development of appropriate dosing equipment has made performing the repeated injections relatively easy; however, only few clinical subcutaneous peptide delivery systems provide sustained peptide release. As a result, frequent injections are needed, which may cause discomfort and additional risks resulting from a poor administration technique. Controlled peptide delivery systems, able to provide required therapeutic plasma concentrations over an extended period, are needed to increase peptide safety and patient compliancy. In this review, we summarize the current peptidergic drugs, future developments, and parenteral peptide delivery systems. Special emphasis is given to porous silicon, a novel material in peptide delivery. Biodegradable and biocompatible porous silicon possesses some unique properties, such as the ability to carry exceptional high peptide payloads and to modify peptide release extensively. We have successfully developed porous silicon as a carrier material for improved parenteral peptide delivery. Nanotechnology, with its different delivery systems, will enable better use of peptides in several therapeutic applications in the near future.
Collapse
Affiliation(s)
- Miia Kovalainen
- Institute of Biomedicine and Biocenter of Oulu, Faculty of Medicine (M.K., K.-H.H.) and Medical Research Center Oulu and Oulu University Hospital (K.-H.H.), Oulu, Finland; Department of Applied Physics, Faculty of Science and Forestry (J.R.), Department of Applied Physics, Faculty of Science and Forestry (V.-P.L.), and School of Pharmacy, Faculty of Health Sciences (M.V., K.J.), University of Eastern Finland, Kuopio, Finland; Department of Pharmacology, Drug Development and Therapeutics (U.P.), and Department of Physics and Astronomy, Faculty of Mathematics and Natural Sciences (J.S.), University of Turku, Finland; and Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (J.M.)
| | - Juha Mönkäre
- Institute of Biomedicine and Biocenter of Oulu, Faculty of Medicine (M.K., K.-H.H.) and Medical Research Center Oulu and Oulu University Hospital (K.-H.H.), Oulu, Finland; Department of Applied Physics, Faculty of Science and Forestry (J.R.), Department of Applied Physics, Faculty of Science and Forestry (V.-P.L.), and School of Pharmacy, Faculty of Health Sciences (M.V., K.J.), University of Eastern Finland, Kuopio, Finland; Department of Pharmacology, Drug Development and Therapeutics (U.P.), and Department of Physics and Astronomy, Faculty of Mathematics and Natural Sciences (J.S.), University of Turku, Finland; and Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (J.M.)
| | - Joakim Riikonen
- Institute of Biomedicine and Biocenter of Oulu, Faculty of Medicine (M.K., K.-H.H.) and Medical Research Center Oulu and Oulu University Hospital (K.-H.H.), Oulu, Finland; Department of Applied Physics, Faculty of Science and Forestry (J.R.), Department of Applied Physics, Faculty of Science and Forestry (V.-P.L.), and School of Pharmacy, Faculty of Health Sciences (M.V., K.J.), University of Eastern Finland, Kuopio, Finland; Department of Pharmacology, Drug Development and Therapeutics (U.P.), and Department of Physics and Astronomy, Faculty of Mathematics and Natural Sciences (J.S.), University of Turku, Finland; and Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (J.M.)
| | - Ullamari Pesonen
- Institute of Biomedicine and Biocenter of Oulu, Faculty of Medicine (M.K., K.-H.H.) and Medical Research Center Oulu and Oulu University Hospital (K.-H.H.), Oulu, Finland; Department of Applied Physics, Faculty of Science and Forestry (J.R.), Department of Applied Physics, Faculty of Science and Forestry (V.-P.L.), and School of Pharmacy, Faculty of Health Sciences (M.V., K.J.), University of Eastern Finland, Kuopio, Finland; Department of Pharmacology, Drug Development and Therapeutics (U.P.), and Department of Physics and Astronomy, Faculty of Mathematics and Natural Sciences (J.S.), University of Turku, Finland; and Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (J.M.)
| | - Maria Vlasova
- Institute of Biomedicine and Biocenter of Oulu, Faculty of Medicine (M.K., K.-H.H.) and Medical Research Center Oulu and Oulu University Hospital (K.-H.H.), Oulu, Finland; Department of Applied Physics, Faculty of Science and Forestry (J.R.), Department of Applied Physics, Faculty of Science and Forestry (V.-P.L.), and School of Pharmacy, Faculty of Health Sciences (M.V., K.J.), University of Eastern Finland, Kuopio, Finland; Department of Pharmacology, Drug Development and Therapeutics (U.P.), and Department of Physics and Astronomy, Faculty of Mathematics and Natural Sciences (J.S.), University of Turku, Finland; and Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (J.M.)
| | - Jarno Salonen
- Institute of Biomedicine and Biocenter of Oulu, Faculty of Medicine (M.K., K.-H.H.) and Medical Research Center Oulu and Oulu University Hospital (K.-H.H.), Oulu, Finland; Department of Applied Physics, Faculty of Science and Forestry (J.R.), Department of Applied Physics, Faculty of Science and Forestry (V.-P.L.), and School of Pharmacy, Faculty of Health Sciences (M.V., K.J.), University of Eastern Finland, Kuopio, Finland; Department of Pharmacology, Drug Development and Therapeutics (U.P.), and Department of Physics and Astronomy, Faculty of Mathematics and Natural Sciences (J.S.), University of Turku, Finland; and Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (J.M.)
| | - Vesa-Pekka Lehto
- Institute of Biomedicine and Biocenter of Oulu, Faculty of Medicine (M.K., K.-H.H.) and Medical Research Center Oulu and Oulu University Hospital (K.-H.H.), Oulu, Finland; Department of Applied Physics, Faculty of Science and Forestry (J.R.), Department of Applied Physics, Faculty of Science and Forestry (V.-P.L.), and School of Pharmacy, Faculty of Health Sciences (M.V., K.J.), University of Eastern Finland, Kuopio, Finland; Department of Pharmacology, Drug Development and Therapeutics (U.P.), and Department of Physics and Astronomy, Faculty of Mathematics and Natural Sciences (J.S.), University of Turku, Finland; and Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (J.M.)
| | - Kristiina Järvinen
- Institute of Biomedicine and Biocenter of Oulu, Faculty of Medicine (M.K., K.-H.H.) and Medical Research Center Oulu and Oulu University Hospital (K.-H.H.), Oulu, Finland; Department of Applied Physics, Faculty of Science and Forestry (J.R.), Department of Applied Physics, Faculty of Science and Forestry (V.-P.L.), and School of Pharmacy, Faculty of Health Sciences (M.V., K.J.), University of Eastern Finland, Kuopio, Finland; Department of Pharmacology, Drug Development and Therapeutics (U.P.), and Department of Physics and Astronomy, Faculty of Mathematics and Natural Sciences (J.S.), University of Turku, Finland; and Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (J.M.)
| | - Karl-Heinz Herzig
- Institute of Biomedicine and Biocenter of Oulu, Faculty of Medicine (M.K., K.-H.H.) and Medical Research Center Oulu and Oulu University Hospital (K.-H.H.), Oulu, Finland; Department of Applied Physics, Faculty of Science and Forestry (J.R.), Department of Applied Physics, Faculty of Science and Forestry (V.-P.L.), and School of Pharmacy, Faculty of Health Sciences (M.V., K.J.), University of Eastern Finland, Kuopio, Finland; Department of Pharmacology, Drug Development and Therapeutics (U.P.), and Department of Physics and Astronomy, Faculty of Mathematics and Natural Sciences (J.S.), University of Turku, Finland; and Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (J.M.)
| |
Collapse
|
20
|
|
21
|
Wang CF, Sarparanta MP, Mäkilä EM, Hyvönen ML, Laakkonen PM, Salonen JJ, Hirvonen JT, Airaksinen AJ, Santos HA. Multifunctional porous silicon nanoparticles for cancer theranostics. Biomaterials 2015; 48:108-18. [DOI: 10.1016/j.biomaterials.2015.01.008] [Citation(s) in RCA: 108] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2014] [Revised: 12/29/2014] [Accepted: 01/20/2015] [Indexed: 02/07/2023]
|
22
|
Kaasalainen M, Rytkönen J, Mäkilä E, Närvänen A, Salonen J. Electrostatic interaction on loading of therapeutic peptide GLP-1 into porous silicon nanoparticles. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2015; 31:1722-9. [PMID: 25604519 DOI: 10.1021/la5047047] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Porous silicon (PSi) nanoparticles' tunable properties are facilitating their use at highly challenging medical tasks such as peptide delivery. Because of many different mechanisms that are affecting the interaction between the peptide and the particle, the drug incorporation into the mesoporous delivery system is not straightforward. We have studied the adsorption and loading of incretin hormone glucagon like peptide 1 (GLP-1) on PSi nanoparticles. The results show that the highest loading degree can be achieved in pH values near the isoelectric point of peptide, and the phenomenon is independent of the surface's zeta potential. In order to study the interaction between the peptide and the nanoparticle, we studied the adsorption with lower concentrations and noticed that also non-Coulombic forces have a big role in adsorption of GLP-1. Adsorption is effective and pH-independent especially on low peptide concentrations and onto more hydrophobic nanoparticles. Reversibility of adsorption was studied as a function of buffer pH. When the loading is compared to the total mass of the formulation, the loading degree is 29%, and during desorption experiments 25% is released in 4 h and can be considered as a reversible loading degree. Thus, the peptides adsorbed first seem to create irreversibly adsorbed layer that facilitates reversible adsorption of following peptides.
Collapse
Affiliation(s)
- Martti Kaasalainen
- Laboratory of Industrial Physics, Department of Physics and Astronomy, University of Turku , FI-20014 Turku, Finland
| | | | | | | | | |
Collapse
|
23
|
Hasanzadeh Kafshgari M, Alnakhli M, Delalat B, Apostolou S, Harding FJ, Mäkilä E, Salonen JJ, Kuss BJ, Voelcker NH. Small interfering RNA delivery by polyethylenimine-functionalised porous silicon nanoparticles. Biomater Sci 2015; 3:1555-65. [DOI: 10.1039/c5bm00204d] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Polyethyleneimine-coated mesoporous silicon nanoparticles efficiently deliver siRNA in glioblastoma cells, subsequently reducing the protein expression of a chemotherapy resistance gene by 70% within 72 hours.
Collapse
Affiliation(s)
- M. Hasanzadeh Kafshgari
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
- Mawson Institute
- University of South Australia
- Adelaide SA 5001
- Australia
| | - M. Alnakhli
- School of Medicine
- Flinders University
- Adelaide
- Australia
| | - B. Delalat
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
- Mawson Institute
- University of South Australia
- Adelaide SA 5001
- Australia
| | - S. Apostolou
- School of Medicine
- Flinders University
- Adelaide
- Australia
| | - F. J. Harding
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
- Mawson Institute
- University of South Australia
- Adelaide SA 5001
- Australia
| | - E. Mäkilä
- Department of Physics and Astronomy
- University of Turku
- FI-20014 Turku
- Finland
| | - J. J. Salonen
- Department of Physics and Astronomy
- University of Turku
- FI-20014 Turku
- Finland
| | - B. J. Kuss
- School of Medicine
- Flinders University
- Adelaide
- Australia
| | - N. H. Voelcker
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
- Mawson Institute
- University of South Australia
- Adelaide SA 5001
- Australia
| |
Collapse
|
24
|
McInnes SJP, Lowe RD. Biomedical Uses of Porous Silicon. ELECTROCHEMICALLY ENGINEERED NANOPOROUS MATERIALS 2015. [DOI: 10.1007/978-3-319-20346-1_5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
25
|
Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release 2014; 200:138-57. [PMID: 25545217 DOI: 10.1016/j.jconrel.2014.12.030] [Citation(s) in RCA: 1166] [Impact Index Per Article: 116.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2014] [Revised: 12/22/2014] [Accepted: 12/23/2014] [Indexed: 12/18/2022]
Abstract
Cancer is a leading cause of death worldwide. Currently available therapies are inadequate and spur demand for improved technologies. Rapid growth in nanotechnology towards the development of nanomedicine products holds great promise to improve therapeutic strategies against cancer. Nanomedicine products represent an opportunity to achieve sophisticated targeting strategies and multi-functionality. They can improve the pharmacokinetic and pharmacodynamic profiles of conventional therapeutics and may thus optimize the efficacy of existing anti-cancer compounds. In this review, we discuss state-of-the-art nanoparticles and targeted systems that have been investigated in clinical studies. We emphasize the challenges faced in using nanomedicine products and translating them from a preclinical level to the clinical setting. Additionally, we cover aspects of nanocarrier engineering that may open up new opportunities for nanomedicine products in the clinic.
Collapse
|
26
|
In vitro assessment of biopolymer-modified porous silicon microparticles for wound healing applications. Eur J Pharm Biopharm 2014; 88:635-42. [DOI: 10.1016/j.ejpb.2014.09.010] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2014] [Revised: 09/18/2014] [Accepted: 09/29/2014] [Indexed: 12/25/2022]
|
27
|
Almeida PV, Shahbazi MA, Mäkilä E, Kaasalainen M, Salonen J, Hirvonen J, Santos HA. Amine-modified hyaluronic acid-functionalized porous silicon nanoparticles for targeting breast cancer tumors. NANOSCALE 2014; 6:10377-87. [PMID: 25074521 PMCID: PMC4234906 DOI: 10.1039/c4nr02187h] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Active targeting of nanoparticles to receptor-overexpressing cancer cells has great potential for enhancing the cellular uptake of nanoparticles and for reducing fast clearance of the nanoparticles from the body. Herein, we present a preparation method of a porous silicon (PSi)-based nanodelivery system for breast cancer targeting, by covalently conjugating a synthesized amide-modified hyaluronic acid (HA(+)) derived polymer on the surface of undecylenic acid-modified thermally hydrocarbonized PSi (UnTHCPSi) nanoparticles. The resulting UnTHCPSi-HA(+) nanoparticles showed relatively small size, reduced polydispersibility, high biocompatibility, improved colloidal and human plasma stability, as well as enhanced cellular interactions and internalization. Moreover, we demonstrated that the enhanced cellular association of UnTHCPSi-HA(+) relies on the capability of the conjugated HA(+) to bind and consequently target CD44 receptors expressed on the surface of breast cancer cells, thus making the HA(+)-functionalized UnTHCPSi nanoparticles a suitable and promising nanoplatform for the targeting of CD44-overexpressing breast tumors and for drug delivery.
Collapse
Affiliation(s)
- Patrick V Almeida
- Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, FI-00014 University of Helsinki, Finland.
| | | | | | | | | | | | | |
Collapse
|
28
|
Osminkina LA, Sivakov VA, Mysov GA, Georgobiani VA, Natashina UА, Talkenberg F, Solovyev VV, Kudryavtsev AA, Timoshenko VY. Nanoparticles prepared from porous silicon nanowires for bio-imaging and sonodynamic therapy. NANOSCALE RESEARCH LETTERS 2014; 9:463. [PMID: 25288909 PMCID: PMC4185383 DOI: 10.1186/1556-276x-9-463] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/30/2014] [Accepted: 08/28/2014] [Indexed: 05/24/2023]
Abstract
Evaluation of cytotoxicity, photoluminescence, bio-imaging, and sonosensitizing properties of silicon nanoparticles (SiNPs) prepared by ultrasound grinding of porous silicon nanowires (SiNWs) have been investigated. SiNWs were formed by metal (silver)-assisted wet chemical etching of heavily boron-doped (100)-oriented single crystalline silicon wafers. The prepared SiNWs and aqueous suspensions of SiNPs exhibit efficient room temperature photoluminescence (PL) in the spectral region of 600 to 1,000 nm that is explained by the radiative recombination of excitons confined in small silicon nanocrystals, from which SiNWs and SiNPs consist of. On the one hand, in vitro studies have demonstrated low cytotoxicity of SiNPs and possibilities of their bio-imaging applications. On the other hand, it has been found that SiNPs can act as efficient sensitizers of ultrasound-induced suppression of the viability of Hep-2 cancer cells.
Collapse
Affiliation(s)
- Liubov A Osminkina
- Department of Physics, Lomonosov Moscow State University, 119991, Moscow, Russia
| | | | - Grigory A Mysov
- Department of Physics, Lomonosov Moscow State University, 119991, Moscow, Russia
| | | | - Ulyana А Natashina
- Department of Physics, Lomonosov Moscow State University, 119991, Moscow, Russia
| | | | - Valery V Solovyev
- Institute of Theoretical and Experimental Biophysics, RAS, Pushino 142290, Russia
| | - Andrew A Kudryavtsev
- Institute of Theoretical and Experimental Biophysics, RAS, Pushino 142290, Russia
| | - Victor Yu Timoshenko
- Department of Physics, Lomonosov Moscow State University, 119991, Moscow, Russia
| |
Collapse
|
29
|
Shrestha N, Shahbazi MA, Araújo F, Zhang H, Mäkilä EM, Kauppila J, Sarmento B, Salonen JJ, Hirvonen JT, Santos HA. Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers. Biomaterials 2014; 35:7172-9. [DOI: 10.1016/j.biomaterials.2014.04.104] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2014] [Accepted: 04/28/2014] [Indexed: 12/21/2022]
|
30
|
Tölli MA, Ferreira MPA, Kinnunen SM, Rysä J, Mäkilä EM, Szabó Z, Serpi RE, Ohukainen PJ, Välimäki MJ, Correia AMR, Salonen JJ, Hirvonen JT, Ruskoaho HJ, Santos HA. In vivo biocompatibility of porous silicon biomaterials for drug delivery to the heart. Biomaterials 2014; 35:8394-405. [PMID: 24985734 DOI: 10.1016/j.biomaterials.2014.05.078] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2014] [Accepted: 05/28/2014] [Indexed: 11/18/2022]
Abstract
Myocardial infarction (MI), commonly known as a heart attack, is the irreversible necrosis of heart muscle secondary to prolonged ischemia, which is an increasing problem in terms of morbidity, mortality and healthcare costs worldwide. Along with the idea to develop nanocarriers that efficiently deliver therapeutic agents to target the heart, in this study, we aimed to test the in vivo biocompatibility of different sizes of thermally hydrocarbonized porous silicon (THCPSi) microparticles and thermally oxidized porous silicon (TOPSi) micro and nanoparticles in the heart tissue. Despite the absence or low cytotoxicity, both particle types showed good in vivo biocompatibility, with no influence on hematological parameters and no considerable changes in cardiac function before and after MI. The local injection of THCPSi microparticles into the myocardium led to significant higher activation of inflammatory cytokine and fibrosis promoting genes compared to TOPSi micro and nanoparticles; however, both particles showed no significant effect on myocardial fibrosis at one week post-injection. Our results suggest that THCPSi and TOPSi micro and nanoparticles could be applied for cardiac delivery of therapeutic agents in the future, and the PSi biomaterials might serve as a promising platform for the specific treatment of heart diseases.
Collapse
Affiliation(s)
- Marja A Tölli
- Department of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, FI-90014 Oulu, Finland
| | - Mónica P A Ferreira
- Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland
| | - Sini M Kinnunen
- Division of Pharmacology and Pharmacotherapy, University of Helsinki, FI-00014 Helsinki, Finland
| | - Jaana Rysä
- Department of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, FI-90014 Oulu, Finland; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, FI-70211 Kuopio, Finland
| | - Ermei M Mäkilä
- Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland; Laboratory of Industrial Physics, Department of Physics and Astronomy, University of Turku, FI-20014 Turku, Finland
| | - Zoltán Szabó
- Department of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, FI-90014 Oulu, Finland
| | - Raisa E Serpi
- Department of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, FI-90014 Oulu, Finland; Faculty of Biochemistry and Molecular Medicine, Biocenter Oulu, University of Oulu, FI-90014 Oulu, Finland
| | - Pauli J Ohukainen
- Department of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, FI-90014 Oulu, Finland
| | - Mika J Välimäki
- Department of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, FI-90014 Oulu, Finland
| | - Alexandra M R Correia
- Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland
| | - Jarno J Salonen
- Laboratory of Industrial Physics, Department of Physics and Astronomy, University of Turku, FI-20014 Turku, Finland
| | - Jouni T Hirvonen
- Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland
| | - Heikki J Ruskoaho
- Department of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, FI-90014 Oulu, Finland; Division of Pharmacology and Pharmacotherapy, University of Helsinki, FI-00014 Helsinki, Finland.
| | - Hélder A Santos
- Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland.
| |
Collapse
|
31
|
Vlasova MA, Rytkönen J, Riikonen J, Tarasova OS, Mönkäre J, Kovalainen M, Närvänen A, Salonen J, Herzig KH, Lehto VP, Järvinen K. Nanocarriers and the delivered drug: effect interference due to intravenous administration. Eur J Pharm Sci 2014; 63:96-102. [PMID: 24964293 DOI: 10.1016/j.ejps.2014.06.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Revised: 05/21/2014] [Accepted: 06/13/2014] [Indexed: 11/28/2022]
Abstract
Intravenously administered nanocarriers are widely studied to improve the delivery of various therapeutic agents. However, recent in vivo studies have demonstrated that intravenously administered nanocarriers that do not contain any drug may affect cardiovascular function. Here we provide an example where the drug and the nanocarrier both affect the same cardiovascular parameters following intravenous administration. The peptide ghrelin antagonist (GhA) increases arterial pressure, while thermally hydrocarbonized porous silicon nanoparticles (THCPSi) transiently decrease it, as assessed with radiotelemetry in conscious rats. As a result, intravenous administration of GhA-loaded THCPSi nanoparticles partially antagonized GhA activity: arterial pressure was not increased. When the cardiovascular effects of GhA were blocked with atenolol pretreatment, GhA-loaded nanoparticles reduced arterial pressure to similar extent as drug-free nanoparticles. These data indicate that the biological activity of a drug delivered within a nanocarrier may be obscured by the biological responses induced by the nanocarrier itself.
Collapse
Affiliation(s)
- Maria A Vlasova
- Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, 70211 Kuopio, Finland.
| | - Jussi Rytkönen
- Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, 70211 Kuopio, Finland
| | - Joakim Riikonen
- Faculty of Science and Forestry, Department of Applied Physics, University of Eastern Finland, 70211 Kuopio, Finland.
| | - Olga S Tarasova
- Department of Human and Animal Physiology, M.V. Lomonosov Moscow State University, Moscow 119234, Russia.
| | - Juha Mönkäre
- Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, 70211 Kuopio, Finland
| | - Miia Kovalainen
- Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, 70211 Kuopio, Finland
| | - Ale Närvänen
- Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, 70211 Kuopio, Finland
| | - Jarno Salonen
- Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland.
| | - Karl-Heinz Herzig
- Institute of Biomedicine & Biocenter of Oulu, University of Oulu, 90014 Oulu, Finland.
| | - Vesa-Pekka Lehto
- Faculty of Science and Forestry, Department of Applied Physics, University of Eastern Finland, 70211 Kuopio, Finland.
| | - Kristiina Järvinen
- Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, 70211 Kuopio, Finland.
| |
Collapse
|
32
|
Santos HA, Mäkilä E, Airaksinen A, Bimbo L, Hirvonen J. Porous silicon nanoparticles for nanomedicine: preparation and biomedical applications. Nanomedicine (Lond) 2014; 9:535-54. [DOI: 10.2217/nnm.13.223] [Citation(s) in RCA: 137] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
The research on porous silicon (PSi) materials for biomedical applications has expanded greatly since the early studies of Leigh Canham more than 25 years ago. Currently, PSi nanoparticles are receiving growing attention from the scientific biomedical community. These nanostructured materials have emerged as promising multifunctional and versatile platforms for nanomedicine in drug delivery, diagnostics and therapy. The outstanding properties of PSi, including excellent in vivo biocompatibility and biodegradability, have led to many applications of PSi for delivery of therapeutic agents. In this review, we highlight current advances and recent efforts on PSi nanoparticles regarding the production properties, efficient drug delivery, multidrug delivery, permeation across biological barriers, biosafety and in vivo tracking for biomedical applications. The constant boost on successful preclinical in vivo data reported so far makes this the ‘golden age’ for PSi, which is expected to finally be translated into the clinic in the near future.
Collapse
Affiliation(s)
- Hélder A Santos
- Division of Pharmaceutical Chemistry & Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland
| | - Ermei Mäkilä
- Division of Pharmaceutical Chemistry & Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland
- Laboratory of Industrial Physics, Department of Physics & Astronomy, University of Turku, Turku, FI-20014, Finland
| | - Anu J Airaksinen
- Laboratory of Radiochemistry, Department of Chemistry, University of Helsinki, Helsinki, FI-00014, Finland
| | - Luis M Bimbo
- Division of Pharmaceutical Chemistry & Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland
| | - Jouni Hirvonen
- Division of Pharmaceutical Chemistry & Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland
| |
Collapse
|
33
|
Herzig KH. Regulatory Peptides--past, present and future. REGULATORY PEPTIDES 2014; 188:iv. [PMID: 24560295 DOI: 10.1016/s0167-0115(14)00012-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/01/2013] [Accepted: 07/09/2013] [Indexed: 06/03/2023]
Affiliation(s)
- Karl-Heinz Herzig
- Institute of Biomedicine and Biocenter of Oulu, Medical Center Oulu and Oulu University Hospital, Oulu, Finland.
| |
Collapse
|
34
|
Effect of surface chemistry of porous silicon microparticles on glucagon-like peptide-1 (GLP-1) loading, release and biological activity. Int J Pharm 2013; 454:67-73. [DOI: 10.1016/j.ijpharm.2013.06.063] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Revised: 06/14/2013] [Accepted: 06/21/2013] [Indexed: 10/26/2022]
|
35
|
Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles. J Control Release 2013; 170:268-78. [PMID: 23756152 DOI: 10.1016/j.jconrel.2013.05.036] [Citation(s) in RCA: 112] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2013] [Revised: 05/30/2013] [Accepted: 05/31/2013] [Indexed: 01/25/2023]
Abstract
Nanoparticulate drug delivery systems offer remarkable opportunities for clinical treatment. However, there are several challenges when they are employed to deliver multiple cargos/payloads, particularly concerning the synchronous delivery of small molecular weight drugs and relatively larger peptides. Since porous silicon (PSi) nanoparticles (NPs) can easily contain high payloads of drugs with various properties, we evaluated their carrier potential in multi-drug delivery for co-loading of the hydrophobic drug indomethacin and the hydrophilic human peptide YY3-36 (PYY3-36). Sequential loading of these two drugs into the PSi NPs enhanced the drug release rate of each drug and also their amount permeated across Caco-2 and Caco-2/HT29 cell monolayers. Regardless of the loading approach used, dual or single, the drug permeation profiles were in good correlation with their drug release behaviour. Furthermore, the permeation studies indicated the critical role of the mucus intestinal layer and the paracellular resistance in the permeation of the therapeutic compounds across the intestinal wall. Loading with PYY3-36 also greatly improved the cytocompatibility of the PSi NPs. Conformational analysis indicated that the PYY3-36 could still display biological activity after release from the PSi NPs and permeation across the intestinal cell monolayers. These results are the first demonstration of the promising potential of PSi NPs for simultaneous multi-drug delivery of both hydrophobic and hydrophilic compounds.
Collapse
|